Arcus Biosciences Announces New Employment Inducement Grants
Now Reading

Arcus Biosciences Announces New Employment Inducement Grants

Announcements, Business

Arcus Biosciences Announces New Employment Inducement Grants

Published on March 26, 2024
 at 09:03 EDT
Source: Pinion Newswire

HAYWARD, Calif.–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and restricted stock units to acquire a total of 9,200 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73, dual A2a/A2b receptor and CD39), AXL and HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on X.

 

Source: Arcus Biosciences

Media Contacts

Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
[email protected]

Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
[email protected]